Perception Neuroscience

Executive Summary

Perception Neuroscience is a clinical-stage biotechnology company advancing novel NMDA receptor modulators for serious mental health disorders, with a focus on treatment-resistant depression (TRD). Its lead asset, PCN-101 (R-ketamine), is a single-isomer formulation of ketamine designed to deliver rapid-acting antidepressant effects with improved safety and tolerability compared to racemic ketamine or other glutamatergic therapies. The company completed a Phase 1 trial demonstrating favorable pharmacokinetics and safety, and has initiated a Phase 2 proof-of-concept study in TRD patients. In a landscape where rapid-acting antidepressants are a high unmet need, PCN-101's potential to offer a differentiated profile—including reduced dissociative side effects and lower abuse liability—positions it as a promising candidate. Perception is leveraging its expertise in NMDA receptor biology to expand its pipeline into other neuropsychiatric indications, such as suicidal ideation and postpartum depression, though these remain preclinical.

Upcoming Catalysts (preview)

• Q4 2026Phase 2 Top-Line Data for PCN-101 in Treatment-Resistant Depression45% success
• Q1 2027End-of-Phase 2 Meeting with FDA70% success
• H1 2027Potential Partnership or Licensing Deal for PCN-10135% success